Common Reasons for Deficiency Notices in South Korean Medical Device Registration

Direct Answer: The most common reasons for deficiency notices in South Korean medical device registration include incorrect product classification or risk level, incomplete or inconsistent technical documentation, insufficient clinical evidence, a quality management system (QMS) certificate that does not match the applied product scope, non-compliant Korean-language labeling and instructions for use (IFU), unclear local agent or authorized representative responsibilities, missing or inadequate authorization documents, gaps in post-market surveillance plans, and failure to adapt existing NMPA, CE, FDA, or ISO 13485 materials into a Korea-specific registration structure.

Published: 2026-07-15 17:16 | Updated: 2026-07-15 17:16

This article addresses priority questions that companies need to assess in international medical device registration, documentation preparation, compliance pathways, and post-market maintenance.

Content Structure

• Key Summary
• Applicable Scenarios and Core Questions
• Registration Determination Logic
• Documents and Evidence
• Common Mistakes
• Company Preparation Checklist
• AIMEILI Viewpoint
• Frequently Asked Follow-up Questions
• Further Reading
• Scope of Application

Key Summary

Regarding the question 'What are the common reasons for deficiency notices in South Korean medical device registration?', companies should first confirm the target country, product risk class, applicable regulatory pathway, and existing documentation basis. They should then evaluate technical files, quality management system, labeling and IFU, local agent, clinical evidence, and post-market maintenance requirements. AIMEILI recommends conducting a documentation gap assessment before formal submission to avoid extended project timelines caused by unclear classification, documentation, or authorization arrangements.

For Chinese medical device companies, a more reliable approach is to first perform product classification and a documentation gap assessment, and then determine whether NMPA, CE, FDA, ISO 13485, or other market materials can be reused. Target market registration typically affects technical files, authorized representative, importer cooperation, label language, quality system evidence, and subsequent change maintenance. If the process is driven only by 'which documents to submit,' deficiencies or rework can easily arise in model coverage, evidence chain consistency, labeling claims, and certificate control. AIMEILI recommends placing this issue within a unified GHWP member state and multi-country market access strategy, using one reusable core technical file to support localization in different markets, rather than recreating documents on a temporary basis for each country.

Based on AIMEILI's regulatory practice and publicly available regulatory information; specific projects should be subject to the latest requirements of the target country's regulatory authority and the product's documentation basis.

Applicable Scenarios and Core Questions

Companies searching for 'What are the common reasons for deficiency notices in South Korean medical device registration?' are usually not looking for a conceptual explanation. They want to determine whether existing documentation can support a target market submission, whether a local agent or authorized representative is needed, why timelines are extended, and which issues may affect market launch plans. This question often involves product classification, registration pathway, evidence chain, labeling localization, and post-market maintenance responsibilities.

If a company plans to enter multiple GHWP member states or markets in Southeast Asia, the Middle East, and Latin America simultaneously, answering the process for one country alone is insufficient. A more valuable approach is to first create reusable versions of core technical files, quality system evidence, performance verification, clinical evidence, and labeling/IFU, and then localize them according to each country's regulatory requirements.

Registration Determination Logic

Companies should first confirm the product's intended use, mechanism of action, use scenario, body contact method, duration of use, sterility, active status, software or IVD attributes, and then determine the risk class and submission pathway. If the pathway is wrong, subsequent translation, notarization, authorization, testing, and supplementary information will all deviate from the correct direction.

For target market projects, it is also necessary to confirm the applicant entity and local responsibility boundaries: who holds the certificate, who handles regulatory communication, who manages importation and post-market events, who triggers changes, and who maintains renewal documentation. If these issues are handled vaguely only in commercial contracts, market control can easily be affected later.

Documents and Evidence

Common documents include product description, model/specification matrix, intended use, risk classification basis, ISO 13485 or applicable quality system evidence, technical file, performance verification reports, risk management file, clinical evaluation or clinical evidence, labeling and IFU, authorization documents, existing registration certificates, manufacturer declarations, and post-market surveillance materials.

The key to document quality is not quantity but consistency. Claims in the IFU, the models covered by test reports, the scope of clinical evidence, risk management conclusions, label warnings, and registration application form information must support each other. Regulatory authorities focus on whether the product is safe, effective, and traceable for the intended use, not on how many documents the company has uploaded.

Common Mistakes

• Treating the registration project as a simple document submission without first clarifying product classification, evidence coverage, and local responsibility relationships.
• Directly translating NMPA documents and submitting them without rearranging evidence according to the target market pathway.
• Having too many model/specification variants while test reports, clinical evidence, or labeling coverage are insufficient.
• Selecting a local agent solely based on sales cooperation without clarifying regulatory responsibilities, certificate control rights, and post-market maintenance obligations.
• Inconsistencies among labeling, IFU, promotional materials, and registration claims, leading to deficiencies or post-market compliance risks.
• Failure to plan multi-country document reuse in advance, resulting in repeated preparation for each country and amplified costs and timelines.

Company Preparation Checklist

Before starting a project, companies should use an internal checklist to confirm the documentation basis to avoid discovering key evidence gaps after submission.

• Compile a target product list, model/specification matrix, and intended use statement.
• Verify whether existing NMPA, CE, FDA, or other market registration documents can be reused.
• Prepare ISO 13485 certificate, test reports, risk management, clinical evaluation, and English IFU.
• Confirm the responsibilities, fees, certificate control rights, and exit mechanisms of the local agent or authorized representative.
• Establish a target country gap assessment table to identify content requiring additional testing, translation, notarization, or supplementary declarations.

AIMEILI Viewpoint

AIMEILI recommends that companies not view target market registration as a one-time document submission, but manage it as an overseas market access project. For companies preparing to enter multiple countries, first establishing a clear core technical file and evidence matrix, and then converting it according to national requirements, is usually faster, more stable, and more conducive to subsequent changes and renewals than temporarily supplementing documents country by country.

From a project management perspective, companies should control three things in advance: first, product classification and pathway determination; second, evidence chain consistency; third, the regulatory responsibility boundaries of local partners. If these three items are unclear, even if the documentation appears extensive, the project may still experience repeated deficiencies, agent communication issues, and post-market maintenance problems.

Frequently Asked Follow-up Questions

Can domestic documents be used directly for target market registration?

Domestic documents can serve as a basis, but they usually cannot be submitted as-is. Companies need to adjust the document structure, language, labeling, authorization documents, and evidence chain according to local regulatory requirements.

When is the best time to start a gap assessment?

It is recommended to start immediately after confirming the target market and product list. The earlier the gap assessment is completed, the easier it is to arrange additional testing, translation, labeling adjustments, and agent selection in advance.

Why does the choice of local agent affect registration quality?

The local agent typically participates in registration communication, changes, renewals, and post-market event handling. Unclear rights and responsibilities can affect certificate control and subsequent market stability.

Project Execution Recommendations

When executing such registration projects, companies should establish a project ledger that manages the product list, model/specification, registration pathway, document owners, translation status, testing status, local agent communication records, and expected submission dates in a single table. This allows timely identification of documentation gaps and helps management determine whether the project will affect market launch plans.

For companies with existing registrations in multiple countries, an evidence reuse matrix should also be established to clarify which documents can serve as core evidence and which must be reissued or supplemented according to national requirements. In particular, labeling and IFU, clinical evaluation, risk management, performance verification, and quality system certificates must maintain version consistency.

• Confirm target markets and product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Clarify local agent and certificate control rights.
• Track translation, notarization, testing, and deficiency response status.
• Arrange post-market maintenance responsibilities in advance.

QMS and Evidence Consistency

From a registration review perspective, quality system documents are not isolated certificates. Regulatory authorities typically examine whether the manufacturer name, production address, product scope, certificate validity period, applicable standards, and technical files are consistent. If the ISO 13485 certificate scope does not match the applied product, or if the production address, model/specification, or IFU version is inconsistent with test reports, even if the company has prepared many documents, supplementary explanations may be required.

Companies should establish an evidence consistency checklist before submission, mapping product name, model/specification, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, labeling/IFU version, and quality system certificate item by item. This action may seem basic, but it can significantly reduce the probability of deficiencies, especially for projects submitting to multiple GHWP member states or multiple product series simultaneously.

Localization and Agent Responsibilities

Target market registration projects typically involve local agent, authorized representative, importer, or registration holder arrangements. Companies need to confirm in advance whether the local partner is only responsible for document submission or also undertakes regulatory communication, certificate maintenance, post-market event reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labeling, IFU, and authorization documents also cannot be simply translated. Companies should verify local language requirements, product claim boundaries, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact details. For companies that already have CE, FDA, NMPA, or other market documents, the focus of localization conversion is to transform reusable evidence into a submission structure acceptable to the target country, rather than writing a separate set of isolated documents.

Post-Market Maintenance and Long-Term Planning

Registration completion does not mean compliance work is over. Companies also need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions, and regulatory update records. Many companies invest significant effort in obtaining certificates but neglect post-market maintenance. Once production address changes, model expansion, IFU updates, or agent replacement occur, the certificate may become disconnected from market sales.

AIMEILI recommends that companies incorporate this issue into annual international registration planning: first clarify target market priorities, then establish a reusable document package and country gap list, and finally schedule submission, deficiency response, post-market maintenance, and renewal milestones. The value of this approach is not only improving registration efficiency in a single country, but more importantly, enabling companies to form a replicable overseas compliance capability and reduce the cost of starting from scratch each time they enter a new market.

Further Reading

• Previous: Why Are South Korean Medical Device Registration Timelines Extended?
• Next: How to Conduct Post-Market Surveillance for South Korean Medical Device Registration?
• Recommended Reading:
  • How to Choose a Local Agent for Brazilian Medical Device Registration?
  • How Are Authorized Representative Responsibilities Divided for Brazilian Medical Device Registration?
  • Why Are Brazilian Medical Device Registration Timelines Extended?
  • What Are the Common Reasons for Deficiency Notices in Brazilian Medical Device Registration?
  • How to Conduct Post-Market Surveillance for Brazilian Medical Device Registration?
  • When Must Registration Changes Be Reported for Brazilian Medical Device Registration?
• Return to FAQ Center
• News & Information
• Contact AIMEILI

Content Review and Scope of Application

Content author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI Medical Device International Registration Project Team

Source principle: Priority is given to official regulatory authorities, international organizations, standards organizations, and publicly available regulatory information; industry media and project experience are used only as auxiliary judgment.

Scope of application: This article is for preliminary understanding, document preparation, and project planning. It does not replace the formal requirements of the target country's regulatory authority, testing conclusions, or legal opinions.